ImportRefusal LogoImportRefusal

Glaxosmithkline Pharmaceuticals

⚠️ High Risk

FEI: 3004459800 • Mumbai, Maharashtra • INDIA

FEI

FEI Number

3004459800

📍

Location

Mumbai, Maharashtra

🇮🇳

Country

INDIA
🏢

Address

Dr Annie Besant Road, , Mumbai, Maharashtra, India

High Risk

FDA Import Risk Assessment

70.4
LowModerateHighCritical

This firm has a significant history of FDA import refusals with notable violations.

Statistics

19
Total Refusals
1
Unique Violations
10/22/2025
Latest Refusal
2/14/2005
Earliest Refusal

Score Breakdown

Violation Severity
90.0×40%
Refusal Volume
48.2×30%
Recency
95.2×20%
Frequency
9.2×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

7519×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

Refusal History

DateProductViolationsDivision
10/22/2025
64LDY07BETAMETHASONE SODIUM PHOSPHATE (GLUCOCORTICOID)
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/3/2025
66VAJ99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/16/2025
60ZAY02ALBENDAZOLE (ANTIPARASITIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/8/2025
56FDY30POLYMYXIN B SULFATE (PEPTIDES)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/8/2025
64LCY03BETAMETHASONE (GLUCOCORTICOID)
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/5/2024
56BDK03AMOXICILLIN TRIHYDRATE (PENICILLIN, SYNTHETICALLY PRODUCED)
75UNAPPROVED
Division of Southeast Imports (DSEI)
11/1/2023
56BDY03AMOXICILLIN TRIHYDRATE (PENICILLIN, SYNTHETICALLY PRODUCED)
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/26/2023
63BDJ25FLUTICASONE PROPIONATE (BRONCHODILATOR)
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/25/2022
60LDA01ACETAMINOPHEN (ANALGESIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
8/26/2021
56DDO49NEOMYCIN, N.E.C. (AMINOGLYCOSIDES)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/24/2019
66VDA99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/30/2019
63FCY06DIGOXIN (CARDIOTONIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/20/2012
66JDB01LEVOTHYROXINE SODIUM (THYROID HORMONE)
75UNAPPROVED
New Orleans District Office (NOL-DO)
2/23/2011
66VIP99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
New Orleans District Office (NOL-DO)
2/23/2011
66VIP99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
New Orleans District Office (NOL-DO)
2/23/2011
66VIP99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
New Orleans District Office (NOL-DO)
10/4/2007
61HCB99ANTI-BACTERIAL, N.E.C.
75UNAPPROVED
New Orleans District Office (NOL-DO)
11/1/2005
60SCA25RANITIDINE HYDROCHLORIDE (ANTACID)
75UNAPPROVED
New Orleans District Office (NOL-DO)
2/14/2005
64LBO67CLOBETASOL PROPIONATE (GLUCOCORTICOID)
75UNAPPROVED
New Orleans District Office (NOL-DO)

Frequently Asked Questions

What is Glaxosmithkline Pharmaceuticals's FDA import refusal history?

Glaxosmithkline Pharmaceuticals (FEI: 3004459800) has 19 FDA import refusal record(s) in our database, spanning from 2/14/2005 to 10/22/2025.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Glaxosmithkline Pharmaceuticals's FEI number is 3004459800.

What types of violations has Glaxosmithkline Pharmaceuticals received?

Glaxosmithkline Pharmaceuticals has been cited for 1 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Glaxosmithkline Pharmaceuticals come from?

All FDA import refusal data for Glaxosmithkline Pharmaceuticals is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.